Nucleus plus
  • Patient Care
  • About
 
 

04.07.22

In Vivo Imaging of Nanoparticle-Labeled CAR T Cells

by ASTCT Science Highlights

Kiru L, Zlitni A, Tousley AM, et al. In Vivo Imaging of Nanoparticle-Labeled CAR T Cells. Proceedings of the National Academy of Sciences. 2022; (doi: 10.1073/pnas.2102363119).

Researchers have identified a successful method for mechanically labeling antigen receptor (CAR) T cells, a development that promises to expand the use of T cell therapy to include solid tumors. The noninvasive technique stamps CAR T cells with ferumoxytol, iron oxide nanoparticles that can then be detected using magnetic resonance imaging, photoacoustic imaging, and magnetic particle imaging. In animal testing, these clinical imaging methods successfully directed T cells to osteosarcomas and off-target sites in subjects that had received infusions of T cells marked with the Food and Drug Administration-approved nanoparticles. In turn, T cells were not visualized in animals infused with unlabeled cells. The ability to track the therapeutic T cells in the tumor is an important advance in the quest to apply CAR T-cell therapy to solid tumors, which has been hindered by the absence of data on the biodistribution of the therapeutic cells in patients. The process described by investigators can be used to monitor T cells during the course of clinical trials.

Read More

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
08.02.22
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
by ASTCT Science Highlights
Single-Cell Antigen-Specific Landscape of CAR T Infusion Product Identifies Determinants of CD19-Positive Relapse in Patients with ALL
07.28.22
Single-Cell Antigen-Specific Landscape of CAR T Infusion Product Identifies Determinants of CD19-Positive Relapse in Patients with ALL
by ASTCT Science Highlights
Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL
07.26.22
Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL
by ASTCT Science Highlights
footer divider

ASTCT

American Society for Transplantation
and Cellular Therapy

330 North Wabash Avenue, Suite 2000
Chicago, IL 60611, USA
Phone: (312) 321-6820
Fax: (312) 673-6733

facebook youtube twitter linkedin
Login
Search